#eli lilly
Related Stories (4)
Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition - Reuters
Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition Reuters
June 30, 2026Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe - Reuters
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe Reuters
June 23, 2026Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
February 23, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (9)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
La acción cae más del 16% y se deja ya un 75% desde mediados de 2024. El grupo danés se queda por detrás de su rival estadounidense Eli Lilly Enésimo desplome de Novo Nordisk en Bolsa. Sus acciones s
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
Novo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects future sales and market position. Eli Lilly's shares saw a rise. I
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-gener
Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's
BenzingaEspañaItalia대한민국日本FrançaisMy AccountBenzinga EdgeBenzinga ResearchBenzinga ProLoginGet Benzinga Pro Data & APIsEventsPremarketAdvertiseContributeEspañaItalia대한민국日本FrançaisLoginRegisterBenzinga
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly
Take advantage of our newsletter subscription and stay informed on the go!
Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa